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Abstract: Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment 
of schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity for the 
5-hydroxytryptamine (5-HT)7 receptor. Lurasidone also has high affinities for the dopamine D2, 
5HT2A, 5-HT1A and α2C adrenergic receptors. Moreover, lurasidone has low affinities for the α1 
adrenergic, histamine H1 and muscarinic M1 receptors. The involvement of 5-HT7 receptors in 
cognitive processes has been suggested by both pharmacological and molecular investigations. 
Chronic treatment with lurasidone increases neurotrophin BDNF mRNA levels in both the 
hippocampus (ventral and dorsal) and prefrontal cortex under basal conditions or in response 
to an acute swim stress. Lurasidone may potentiate N-methyl-D-aspartate receptor (NMDAR) 
function through antagonistic action on 5-HT7 receptors without a direct affinity for NMDARs. 
These results suggest that lurasidone treatment may be a novel approach for the prevention of 
the development of cognitive impairment in individuals who are at risk for schizophrenia or 
related disorders involving cognitive impairment. In clinical trials, treatment with lurasidone 
was associated with significantly greater endpoint improvement versus placebo on the Positive 
and Negative Syndrome Scale total score after 6 weeks among subjects receiving 80 or 160 mg. 
The most frequent side effects of lurasidone were akathisia, nausea, parkinsonism, dizziness and 
somnolence. Once-daily treatment with lurasidone at 160 mg was superior to placebo based on 
the composite cognitive functioning measure. Lurasidone treatment produced improvements in 
Montgomery–Asberg Depression Rating Scale scores at 6 weeks that were significantly greater 
than placebo. A limitation of this review is that the majority of the data were obtained from 
abstracts and posters. These sources have not been subjected to the peer review processes of 
medical journals; thus, the results presented in these forums may require further quality review 
and subsequent revision prior to final publication.
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Introduction
Schizophrenia is a multidimensional and severely disabling psychiatric disease that 
strongly needs improved pharmacological interventions that produce better adherence, 
better long-term outcomes and better patient functionality. Symptom severity and the 
long-lasting, chronic patterns of schizophrenia often cause a high degree of disability. 
Support for the neurodevelopmental model of schizophrenia comes from a variety of 
research paradigms and suggests that cognitive abnormality is an independent, core 
feature of the illness.1–3
At the time of their first identified schizophrenic episode, patients have cognitive 
impairments with similar profiles and nearly identical severities as those of people with 
a more chronic course of the illness.4 Cognitive impairments are also observed prior 
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to the onset of the full clinical syndrome (Figure 1),5–10 and 
deficits in multiple domains of cognition, including work-
ing memory, declarative memory, and executive function, 
often lead to severe functional impairment from the time of 
diagnosis.11,12 Abnormalities in the prefrontal cortex (PFC) 
and temporal cortex are considered to be the most likely 
basis of the cognitive impairments seen in schizophrenia.13,14 
While there is evidence of cognitive deficits before the onset 
of the illness, there is limited knowledge as to when cogni-
tive dysfunction emerges and how the subsequent deficits 
progress throughout childhood and adolescence.
Furthermore, in schizophrenia, mood symptoms seem to 
affect everyday functioning in a way that is unassociated with 
the severity of deficits in cognition and functional capacity.15 
Depression in schizophrenia is no longer considered to be a 
phenomenon that only occurs during periods of partial recov-
ery from psychosis. It is now widely known that depression 
occurs during all phases of the illness and affects everyday 
functioning (Figure 1).16
The aim of this review is to provide an update on the 
development of lurasidone treatment from the preclinical 
research data to the results of clinical trials in patients with 
schizophrenia.
Pharmacodynamics
Lurasidone is a novel benzoisothiazol antipsychotic drug 
(APD) that was approved for treatment of schizophrenia 
by the US Food and Drug Administration (FDA) in 2010. 
  Figure 2 shows the receptor-binding profile of lurasidone. 
The signature receptor-binding profile of lurasidone is its high 
affinity for antagonistic action at the 5-hydroxytryptamine 
(5-HT)7 receptor. The affinity of lurasidone for the 5-HT7 
receptor is the highest within its class of drugs. Lurasidone also 
has high affinity for the dopamine D2, 5HT2A and other receptors 
associated with cognitive function (eg, 5-HT1A and α2C). 
Moreover, lurasidone’s weak affinity for the α1 adrenergic, 
histaminergic H1 or muscarinic M1 receptors suggests lower 
incidence of unpleasant side effects including cognitive 
deficits. Lurasidone’s receptor profile suggests its potential to 
unlock procognitive action through serotonin receptors such 
as the 5-HT7 and 5-HT1A receptors.17–19 Clinical trials have 
shown that lurasidone is a safe and effective treatment for 
schizophrenia with minimal extrapyramidal, cardiovascular, 
or metabolic complications.20–25
Animal models of cognition
Although the molecular mechanism by which APDs improve 
cognition is not fully known, the involvement of 5-HT7 
receptors in cognitive processes has been suggested by 
both pharmacological and genetic tools.26,27 Lurasidone has 
been reported to improve acute MK-801-induced memory 
impairment in rats,28,29 as well as subchronic phencyclidine 
(PCP, a noncompetitive N-methyl-D-aspartate [NMDA] 
antagonist)-induced cognitive impairment in novel object 
recognition (NOR).30,31 In addition, lurasidone enhances 
performance in object retrieval with detour tasks (ORD), 
which have been used to test executive function in the 
common marmoset, a nonhuman primate.32 Recently, 5-HT7 
antagonism has been shown to contribute to the ability 
of lurasidone to improve NOR and the MK-801-induced 
impairment of learning and memory in the passive avoidance 
and Morris water-maze tests in rats.33–35
Pharmacologic early intervention during the ‘prodromal’ 
stage of schizophrenia, before positive and negative symp-
toms reach syndromal levels of severity, is a major goal of 
current strategies for improving outcome and minimizing 
the cost of these syndromes.36,37 Treatment of individuals in 
the prodromal period or at high risk for these disorders with 
atypical APDs has been reported to reduce the rate of progres-
sion to first-episode psychosis in some individuals.38,39
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Figure 1 Schizophrenia progression.
Notes: Schizophrenia is characterized by positive symptoms (delusions and hallucinations), negative symptoms (eg, affective flattening, anhedonia, anergia), abnormalities in 
mood, and cognition deficits and often leads to severe functional impairment from the time of diagnosis.
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Lurasidone was administered along with PCP during the 
period in which the enduring deficits in NOR and other types 
of cognition are developing due to the cumulative effects of 
relatively low-dose PCP. Lurasidone prevented the develop-
ment of PCP-induced cognitive impairment in NOR in rats. 
Subsequent subchronic treatment with lurasidone also had a 
long-lasting (2 weeks) ameliorative effect on PCP-induced 
NOR deficits.40 These results have given rise to the suggestion 
that lurasidone may be a novel approach for preventing the 
development of cognitive impairment in individuals who are 
at risk for schizophrenia or related disorders with cognitive 
impairment.
Neuroadaptive changes: BDNF
Inappropriate neurotrophic support during brain development 
could lead to a structural disorganization in which neuronal 
networks are established in a nonoptimal manner. Inadequate 
neurotrophic support in adult individuals could ultimately be 
an underlying mechanism that leads to a decreased capacity 
of the brain to adaptively change and an increased vulner-
ability to neurotoxic damage. Brain-derived neurotrophic 
factor (BDNF) is a mediator involved in neuronal survival, 
cellular resiliency and cellular plasticity in response to dop-
aminergic, cholinergic, and serotonergic inputs in the central 
nervous system.41
Chronic treatment with lurasidone increases neurotrophin 
BDNF mRNA levels in both the hippocampus (ventral and 
dorsal) and prefrontal cortex under basal conditions or in 
response to an acute swim stress.42,43 The adaptive changes 
under challenging conditions produced by repeated treat-
ments with lurasidone may contribute to the amelioration of 
functional capacities and be closely associated with neuronal 
plasticity, both of which are deteriorated in patients with 
schizophrenia.
Glutamatergic systems:  
NMDA receptors
The first electrophysiological evidence showed that in vivo 
administration of lurasidone produces a significant enhance-
ment of NMDA receptor-mediated excitatory postsynaptic 
currents (EPSC) in PFC neurons. Moreover, administration 
of a single dose of lurasidone restored NMDAR responses in 
subchronic PCP-treated rats. The selective 5-HT7 antagonist 
SB-269970 mimicked the enhancing effect of lurasidone 
on NMDAR-EPSC, while the D2 antagonist haloperidol 
(a typical APD) was ineffective. These results suggest that 
antagonism of 5-HT7 receptors may contribute to the ability 
of lurasidone to potentiate NMDAR function.44 Biochemical 
evidence indicates that surface levels of the NR2A and NR2B 
subunits of the NMDA receptor are selectively and sig-
nificantly elevated after lurasidone administration. Because 
the availability of NR2 subunits determines the number of 
functional NMDARs at synapses, these results suggest that 
the potential molecular mechanism underlying the enhancing 
effect of in vivo administration of lurasidone on NMDAR 
synaptic responses is the increased delivery or decreased 
internalization of synaptic NMDA receptors.44
These results suggest that lurasidone may potentiate 
NMDAR function through antagonistic actions on 5-HT7 
receptors.
Metabolomics
The metabolomic “signature” of lurasidone has been inves-
tigated in a Phase III study using clinical blood samples 
obtained from patients with schizophrenia (ClinicalTrials.
gov Identifier: NCT00615). Patterns of change in the 
metabolome can be interpreted as a molecular phenotype, 
either of a disease state or of the characteristic effect of a 
drug on an organism. In the lurasidone group, the serum 
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levels of 3% of tested biochemicals were significantly 
changed. In contrast, 14% of biochemicals in groups receiv-
ing olanzapine were significantly changed. Treatment with 
lurasidone or olanzapine resulted in significantly increased 
serum levels of glutamate, glycine, and serine relative to 
placebo.45 Increases in blood glutamate were associated 
with improvements in negative symptoms among subjects 
responding to lurasidone treatment. Lurasidone-responders 
with high levels of improvement in negative symptoms had 
a significantly higher increase in glutamate levels compared 
to lurasidone-responders with low levels of improvement in 
negative symptoms.45
In this exploratory metabolomics analysis of schizo-
phrenia responders, treatment with lurasidone did not have 
biochemically different effects than treatment with placebo, 
while treatment with olanzapine was associated with a higher 
proportion of distinct biochemical changes relative to placebo. 
These findings need to be confirmed using larger samples that 
include both treatment-responders and nonresponders.45 Data 
obtained from blood metabolomic profiling in the lurasidone 
clinical trial are consistent with the hypothesis that, based 
on its pharmacological profile, lurasidone treatment may be 
associated with enhanced glutamate activity.
Depression
Lurasidone has a high affinity for the 5-HT7 receptor, to 
which it functions as an antagonist. Lurasidone also has a 
moderate affinity for the 5-HT1A receptors, to which it func-
tions as a partial agonist. Several lines of evidence have 
implicated both 5-HT7 receptor antagonism and 5-HT1A 
partial agonism as central mediators of antidepressant activity 
in animal behavioral models.46–49
Lurasidone has demonstrated antidepressant-like prop-
erties in olfactory bulbectomy models in rats.17 In addition, 
lurasidone reduced immobility, an antidepressant-like effect, 
in both the tail suspension and forced swim tests in wild-
type 5-HT7
+/+ mice but not in 5-HT7
-/- mice.   Furthermore, 
the combination treatment of individually ineffective 
doses of lurasidone and citalopram (an antidepressant of 
the selective serotonin reuptake inhibitors [SSRIs] group) 
also induced an antidepressant-like response in both tests. 
In the repeated open-space swim model, which is a model 
of depression requiring chronic treatment, lurasidone had 
antidepressant effects that were similar to citalopram in 
magnitude.50 The results from the acute mouse models 
suggest that the antidepressant effect of lurasidone require 
functional 5-HT7 receptors. Though lurasidone lacks mono-
amine reuptake-inhibiting effects, the high 5-HT7 receptor 
affinity of lurasidone can synergistically interact with SSRIs 
to provide antidepressant-like effects that require the 5-HT7 
receptors.
Clinical developments:  
short-term trials
Comprehensive review of Phase II/III data evaluating the 
efficacy and safety of lurasidone in short-term schizophrenia 
treatment trials is published in several articles.23–25,51,52
Three multinational, 6-week, double-blind, placebo- and 
active comparator-controlled, randomized Phase III studies 
have been completed, two of which formed the basis for the 
approval of the drug by the FDA.24 The third Phase III trial 
(PEARL 3, ClinicalTrials.gov Identifier: NCT00790192) was 
completed after the New Drug Application was submitted in 
2011. The PEARL 3 was the only pivotal trial that included 
the highest clinical dose of 160 mg/day with a 3-day initial 
titration from 120 mg/day.
The primary measure of endpoint efficacy in all three 
Phase III trials was the mean change in the Positive and 
Negative Symptoms of Schizophrenia Scale (PANSS) total 
score from baseline to endpoint. A key secondary endpoint 
was the change in the Clinical Global Impression of Severity 
scale (CGI-S). The PEARL 3 was the only trial that evalu-
ated cognitive efficacy with a computerized system and the 
University of California San Diego (UCSD) Performance-
based Skills Assessment, Brief (UPSA-B), which assesses 
the capacity for functioning.53
PEARL 3: efficacy and safety
The efficacy and safety of lurasidone (80 mg/day and 
160 mg/day) in patients with an acute exacerbation of schizo-
phrenia was evaluated in hospitalized patients who met the 
DSM-IV criteria for schizophrenia (PANSS total score . 80). 
Patients were randomized in a 6-week, double-blind study 
in which they were treated with lurasidone at 80 mg or 
160 mg, quetiapine XR 600 mg (QXR; included to confirm 
assay sensitivity), or placebo, administered once-daily in the 
evening. Outcome measures included the PANSS, CGI-S, the 
Montgomery–Asberg Depression Rating Scale (MADRS), 
and the Epworth Sleepiness Scale (ESS).
Treatments with lurasidone were associated with 
significantly greater endpoint improvements at 6 weeks on 
the PANSS total score vs placebo (-10.3) among subjects 
in the 80 mg (-22.2; P , 0.001) and 160 mg (-26.5; 
P , 0.001) dosage groups. Significant endpoint improve-
ment was observed in both the CGI-S versus placebo (-0.9) 
during treatment with either 80 (-1.5; P , 0.001) or 160 mg 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
110
Yasui-FurukoriDrug Design, Development and Therapy 2012:6
(-1.7; P , 0.001) doses of lurasidone. Significant differences 
in PANSS total scores occurred between the lurasidone 
treatment groups and placebo by Day 4. QXR produced 
significantly greater endpoint improvement than placebo on 
the PANSS total score (-27.8 vs -10.3; P , 0.001) and the 
CGI-S (-1.7 vs -0.9; P , 0.001). Significant improvements 
in PANSS total scores were found at day 4 and all subsequent 
study visits for both lurasidone groups.53
In this study, treatments with once-daily lurasidone at 
doses of 80 mg or 160 mg were not associated with dose-
related increases in adverse events or adverse event-related 
discontinuations. The most frequent events on lurasidone 
were akathisia, nausea, parkinsonism, dizziness, and som-
nolence (all occurred in ,10% of subjects, Table 1). In the 
placebo-controlled trials with lurasidone up to 120 mg/day, 
akathisia was a dose-related adverse event.21,54 However, 
the incidence of akathisia in patients receiving lurasidone at 
160 mg/day was not a dose-related adverse event.53   Akathisia 
is a common side effect of drugs like antipsychotics and 
SSRIs, but it also occurs spontaneously in patients with 
Parkinson’s disease. Several lines of evidence suggest that 
akathisia can be attributed to low activity of the dopamin-
ergic projections from the midbrain to the ventral striatum. 
However, the exact pathophysiological mechanism of this 
extrapyramidal symptom remains unclear.55
Treatments with lurasidone at 80 mg and 160 mg 
were associated with mean increases in weight that 
were not s  ignificantly different from placebo (+0.6 kg 
and +0.6 kg vs +0.1 kg, respectively); however, the mean 
increase in weight was higher vs placebo for QXR (+2.1 kg).55 
Total cholesterol and triglycerides were decreased at endpoint 
on both doses of lurasidone but were increased on QXR.55
The above data support the results of a post hoc analysis 
of the data from PEARL 2. In this analysis, the 6-week 
olanzapine-controlled study found that lurasidone and 
placebo had similar acute effects on 10-year Framingham 
coronary heart disease (CHD) risk scores, while olanzapine 
was associated with higher risks than placebo in male 
patients.23,56
Treatments with 80 mg or 160 mg of lurasidone 
  administered once-daily in the evening were associated with 
reductions in daytime sleepiness that were similar in mag-
nitude to placebo. In contrast, treatment with QXR 600 mg 
was associated with a significant increase in self-reported 
daytime sleepiness (based on ESS assessment) compared to 
placebo.55 These findings indicate overall daytime sleepiness 
might be a mediator of change in clinical or performance-
based functional outcomes, while sleepiness as a mediator 
of cognitive performance is more dependent on the specific 
situation for which sleepiness is reported.
PEARL 3: cognition
The results of the large-scale CATIE study suggested 
that atypical antipsychotic medications may not have 
Table 1 Most common adverse events ($5% and $2× placebo) in two acute schizophrenia studies
Preferred term PEARL 2 study21 PEARL 3 study53
LUR 
40 mg/d 
(n = 119)
LUR 
120 mg/d 
(n = 118)
OLA 
15 mg/d 
(n = 122)
Placebo 
(n = 116)
LUR 
80 mg/d 
(n = 125)
LUR 
160 mg/d 
(n = 121)
QXR 
600 mg/d 
(n = 119)
 
Placebo 
(n = 121)
Akathisia 14 (11.8) 27 (22.9) 9 (7.4) 1 (0.9) 10 (8.0) 9 (7.4) 2 (1.7) 1 (0.8)
Somnolence 12 (10.1) 18 (15.3) 11 (9.0) 5 (4.3) 5 (4.0) 8 (6.6) 16 (13.4) 1 (0.8)
Sedation 11 (9.2) 16 (13.6) 18 (14.8) 4 (3.4) – – – –
Parkinsonism 11 (9.2) 13 (11.0) 6 (4.9) 2 (1.7) 7 (5.6) 8 (6.6) 4 (3.4) 0
Nausea 13 (10.9) 9 (7.6) 6 (4.9) 5 (4.3) 10 (8.0) 8 (6.6) 4 (3.4) 4 (3.3)
weight increase 2 (1.7) 2 (1.7) 25 (20.5) 6 (5.2) 1 (0.8) 2 (1.7) 8 (6.7) 1 (0.8)
Dystonia 4 (3.4) 9 (7.6) 1 (0.8) 1 (0.9) – – – –
Agitation 14 (11.8) 7 (5.9) 8 (6.6) 6 (5.2) – – – –
Dizziness 5 (4.2) 6 (5.1) 3 (2.5) 2 (1.7) 6 (4.8) 7 (5.8) 16 (13.4) 2 (1.7)
Restlessness 7 (5.9) 4 (3.4) 4 (3.3) 3 (2.6) – – – –
Salivary hypersecretion 2 (1.7) 8 (6.8) 1 (0.8) 0 (0.0) – – – –
Musculoskeletal stiffness 3 (2.5) 6 (5.1) 3 (2.5) 2 (1.7) – – – –
Appetite decreased 6 (5.0) 1 (0.8) 2 (1.6) 2 (1.7) – – – –
Dry mouth 2 (1.7) 3 (2.5) 12 (9.8) 1 (0.9) 2 (1.6) 2 (1.7) 9 (7.6) 1 (0.8)
Constipation – – – – 3 (2.4) 1 (0.8) 8 (6.7) 3 (2.5)
Arthralgia – – – – 2 (1.8) 1 (0.8) 7 (5.9) 1 (0.8)
URi – – – – 2 (1.6) 1 (0.8) 6 (5.0) 1 (0.8)
Note: Data shows number of patients (%).
Abbreviations: LUR, lurasidone; OLA, olanzapine; QXR, quetiapine XR; URi, upper respiratory tract infection.
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beneficial effects on cognition.57,58 However, the CATIE 
trial   specifically recruited clinically stable patients, did not 
include placebo controls, and did not require fixed doses of 
antipsychotic medications. This study examined cognitive 
functioning in initially unstable patients with schizophrenia 
(PANSS total score at baseline: mean = 97.4, SD = 10.5, 
N = 482).59 Both cognitive performance and UPSA-B were 
examined at acute phase baseline after 6 weeks and at 3 and 
6 months in the flexible-dose extension phase of double-blind 
treatment with QXR.
Once-daily treatment with lurasidone at 160 mg was 
  superior to both placebo (P , 0.05, d = 0.25) and QXR 
treatment (P , 0.05, d = 0.28) on the composite cognitive 
functioning measure, while QXR, lurasidone 80 mg, and 
placebo did not differ from each other. UPSA-B scores were 
also superior to placebo at the 6-week endpoint for all active 
treatments. The lurasidone benefit over QXR was sustained 
(d = 0.25) at the 6-month endpoint.59
This is the first pharmacological study to date in which the 
investigational treatment was superior to placebo on cognitive 
assessments and a functional co-primary measure (UPSA-B) 
at a 6-week endpoint, as well as to demonstrate superiority to 
an active comparator on neurocognitive improvement over an 
initial 6-week acute phase and subsequently over a 6-month 
extension study period. These findings will require replica-
tion, but cannot be attributed to practice effects because of 
the placebo corrections.
PEARL 3: depression
Both doses of lurasidone and QXR produced significantly 
(P , 0.001) greater improvements in MADRS scores than 
placebo at the 6-week endpoint.55
In Study D1050196, lurasidone (80 mg/day)   demonstrated 
significant efficacy compared to placebo on the MADRS in 
acute patients with schizophrenia. Lurasidone also demon-
strated significant effects in a post hoc analysis of the sub-
group of patients (62.8% of total intent-to-treat  population) 
with elevated levels of depressive symptomatology (base-
line MADRS $ 12; mean = 18.7). The effect size was 
0.44 (MADRS change at 6-week endpoint; P = 0.033).20 
  Lurasidone (80 mg/day) demonstrated replicable significant 
improvements in the MADRS.
Summary
Schizophrenia is a major public health problem and a 
burden on families and the community. It tends to be a 
lifelong disorder requiring multimodal treatments and 
support at all stages of illness. The cause of the illness is 
still unknown. Current treatments focus on eliminating 
symptoms with antipsychotic medications and various 
psychosocial treatments.
In schizophrenia, neurocognition is the most robust 
  predictor of current functional status.60–62 In fact, some 
research suggests that neurocognition is more consistently 
related to functioning than symptom severity.63,64 Even in the 
prodromal phase, before the onset of frank psychosis, cogni-
tive deficits significantly predict subsequent diagnosis.65
The current predominant dopamine hypothesis of 
  schizophrenia might be characterized by an imbalance 
between subcortical and cortical dopamine systems, based 
on functional brain imaging study in altered PFC functions 
and preclinical studies emerged the importance of prefrontal 
dopamine transmission at D1 receptors (the main dopamine 
receptor in the neocortex) for optimal PFC performance.66,67 
The subcortical mesolimbic dopamine projections might be 
hyperactive, resulting in hyperstimulation of D2 receptors and 
positive symptoms, while mesocortical dopamine projections 
to the PFC might be hypoactive, resulting in hypostimulation 
of D1 receptors in PFC which might be implicated in the cogni-
tive impairments and negative symptoms of schizophrenia.68,69 
The 5-HT7 receptor antagonist prevents the inhibition of 
dopamine neuronal firing activity induced by amphetamine 
in the ventral tegmental area, but not in the substantia nigra 
pars compacta. This suggests that 5-HT7 receptors modulate 
preferentially the mesocorticolimbic pathway.70
Over the last several years, a number of studies have 
attempted to evaluate the role of the 5-HT7 receptor in psychi-
atric and neurological disorders. For most of these disorders, 
the results have been mixed with inconsistencies between 
species and the pharmacological and genetic manipulations 
performed.71 Possible reasons for these discrepancies are dif-
ferences in the type and concentration of drug administered, 
timing and site (systemic or central) of administration, type 
of behavioral test, interaction with other neurotransmission 
systems.72–74 Nevertheless, the research conducted so far, and 
reported in this paper, suggests an important participation of 
5-HT7 receptors on cognitive functions, treatment of cogni-
tive disorders, considering the ability of antipsychotic and 
antidepressant drugs to interact with the 5-HT7 receptor.
The 5-HT7 receptor is one of the most recently   discovered 
5-HT receptors. The highest density of 5-HT7 receptor 
expression in the brain has been described in the hypothala-
mus, thalamus, hippocampus, and frontal cortex.75–77 This 
widespread central distribution suggests multiple roles in 
circadian rhythm, thermoregulation, sleep, affective disor-
ders, and is important for cognitive functions.
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In vivo lurasidone administration selectively increases 
the surface level of NMDAR NR2 subunits, which may 
account for the potentiation of NMDAR-mediated synaptic 
responses in the frontal cortex. The 5-HT7 receptor is one 
of the potential receptors underlying the enhancement of 
NMDAR–EPSCs by lurasidone. Lurasidone is capable of 
reversing the NMDAR hypofunction induced by repeated 
PCP treatment, which is a widely studied animal model of 
schizophrenia.44 Moreover, the ability of lurasidone to reverse 
the PCP-induced NOR deficit is blocked by the 5-HT7 ago-
nist AS19.33 Repeated exposure to lurasidone increases the 
mRNA and protein levels of BDNF, an important determinant 
of the synaptic plasticity of glutamatergic synapses.42
In the PEARL 3 study, lurasidone administered once-
daily in the evening at 80 mg and 160 mg demonstrated supe-
riority compared to placebo in terms of PANSS total scores. 
Significant improvements were demonstrated at day 4 and at 
all subsequent study visits. Lurasidone was well-tolerated, 
displaying no clinically significant dose-related increase in 
adverse events. Treatment with lurasidone was associated 
with minimal changes in metabolic parameters. Significant 
increases in weight and lipids were observed for QXR com-
pared to placebo. In addition, lurasidone demonstrated sig-
nificant improvements that were superior to placebo on both 
cognitive assessments and a functional measure (UPSA-B) at 
a 6-week endpoint. Lurasidone also demonstrated superior-
ity to an active comparator on neurocognitive improvement 
over an initial 6-week acute phase and subsequently over a 
6-month extension study period.
The known receptor-binding profile, in combination 
with animal model evidence and data from schizophrenia 
trials indicating improvement in cognitive functioning and 
depressive symptoms, suggests the potential for precognitive 
and antidepressant efficacy of lurasidone in patients with 
schizophrenia.
Cognitive function in schizophrenia is one of the most 
critical determinants of quality of life and function in 
schizophrenia. Lurasidone may be functionally effective 
for the treatment of schizophrenia with underlying cognitive 
dysfunctions and associated comorbid depression. Further, 
lurasidone may have the potential to alter the trajectory of 
the illness for those at highest risk and reduce the burden on 
individuals and their families.
Overall, lurasidone at a once-daily dose in the range of 
40–160 mg was well-tolerated and produced no clinically 
significant dose-related increases in adverse events. 
This was true even at a dose of 160 mg, which is above 
the recommended maximum dose of 80 mg/day in the 
US package insert. Treatment with lurasidone was associated 
with a relatively low incidence of extrapyramidal symptoms. 
Furthermore, lurasidone was associated with low potentials 
for weight gain, daytime sleepiness, adverse metabolic or 
QTc effects, and minimal effects on prolactin.
A limitation of this review is that the majority of the data 
were obtained from abstracts and posters. These sources have 
not been subjected to the peer review processes of medical 
journals, and the results presented in these forums may be 
subject to further quality review and subsequent revision 
prior to final publication.
The product label is the most authoritative source of infor-
mation on lurasidone.78 The current labeling for lurasidone 
recommends doses of 40–80 mg/day, and additional data 
from the PEARL 3 study showing the efficacy of 160 mg/day 
doses are under review by the FDA.
The effectiveness of lurasidone in schizophrenia 
beyond six weeks has not been clarified in controlled 
studies. Other therapeutic properties of lurasidone for the 
treatment of acute bipolar depression (as a monotherapy 
and an adjunctive therapy) and maintenance trials are 
being evaluated. In addition, two trials for the treatment 
of major depressive disorder with mixed features as dis-
cussed in the DSM-5 Mood Disorders Work Group have 
been registered at http://www.clinicaltrials.gov. Another 
registration Phase III trial for treatment of schizophrenia 
is under way in Japan.
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